Baseline characteristics associated with survival in patients with hepatocellular carcinoma

Background and Aim: Hepatocellular carcinoma (HCC) is one of the most common and most lethal cancers worldwide. The objective of this study was to investigate the relationship between basal parameters and survival characteristics in patients with HCC. Materials and Methods: The records of 1447 HCC patients of a tertiary center during the period 2000-2017 were screened retrospectively. The demographic details; basal clinical, laboratory, and radiological characteristics; treatments; and survival time were recorded and prognostic scores were calculated. Results: A total of 788 patients with HCC (male/female: 623/165; mean age: 60.5±10.9 years) were included in the study. The median length of sur- vival was 26.3 months (95% confidence interval [CI], 22.3-30.4 months). The 5-year survival rate was 28.1%. The number and diameter of the tu- mors; platelet count; platelet-to-lymphocyte ratio; level of aspartate ami- notransferase, alanine aminotransferase, and gamma-glutamyl transferase; portal and hepatic vein involvement; and an alpha-fetoprotein level of <9.6 ng/mL were found to be independently related to survival. Conclusion: The positive predictive value of the prognostic index derived from independent survival-related parameters for 5- and 10-year survival or overall survival was approximately 86%. Integration of this prognostic index to the criteria used in making treatment decisions for patients with HCC should be considered.

Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Glob- al cancer statistics 2018: GLOBOCAN estimates of incidence and mor- tality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68(6):394-424.
2. Sanyal A, Yoon S, Lencioni R. The etiology of hepatocellular carcinoma and consequences for treatment. Oncologist 2010;15(S4):14-22.
3. Paul S, Dhamija E, Kedia S. Non-alcoholic fatty liver disease associated with hepatocellular carcinoma: An increasing concern. Indian J Med Res 2019;149(1):9.
4. Uzunalimoğlu Ö, Yurdaydin C, Çetinkaya H, Sahin T, Colakoğlu S, Tankurt E, et al. Risk Factors for Hepatocellular Carcinoma in Turkey. Dig Dis Sci 2001;46(5):1022-1028.
5. Can A, Dogan E, Bayoglu I, Tatli A, Tatli AM, Besiroglu M, Kocer M, et al. Multicenter epidemiologic study on hepatocellular carcinoma in Turkey. Asian Pac J Cancer Prev 2014;15(6):2923-2927.
6. Akkiz H, Carr B, Yalçın KK, Guerra V, Kuran S, Altıntaş E, et al. Charac- teristics of hepatocellular carcinoma aggressiveness factors in Turkish pa- tients. Oncology 2017;94(2):116-124.
7. Ekinci O, Baran B, Ormeci A, Soyer OM, Gokturk S, Evirgen S, et al. Cur- rent state and clinical outcome in Turkish patients with hepatocellular carci- noma. World J Hepatol 2018;10(1):51-61.
8. Alacacioglu A, Somali I, Simsek I, Astarcioglu I, Ozkan M, Camci C, et al. Epidemiology and survival of hepatocellular carcinoma in Turkey: outcome of multicenter study. Jpn J Clin Oncol 2008;38(10):683-688.
9. El-Serag H. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology. 2012;142(6):1264-1273.e1.
10. Gurol E, Saban C, Oral O, Cigdem A, Armagan A. Trends in hepatitis B and hepatitis C virus among blood donors over 16 years in Turkey. Eur J Epidemiol. 2006;21(4):299-305.
11. Tozun N, Ozdogan O, Cakaloglu Y, Idilman R, Karasu Z, Akarca U, et al. Seroprevalence of hepatitis B and C virus infections and risk factors in Tur- key: a fieldwork TURHEP study. Clin Microbiol Infect. 2015;21(11):1020- 1026.
12. Schütte K, Bornschein J, Kahl S, Seidensticker R, Arend J, Ricke J, et al. Delayed diagnosis of hcc with chronic alcoholic liver disease. Liver Cancer. 2012;1(3-4):257-266.
13. Wu G, Wu J, Wang B, Zhu X, Shi X, Ding Y. Importance of tumor size at diagnosis as a prognostic factor for hepatocellular carcinoma survival: a population-based study. Cancer Manag Res 2018;10:4401-4410.
14. Mazzaferro V, Llovet J, Miceli R, Bhoori S, Schiavo M, Mariani L, et al. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol 2009;10(1):35-43.
15. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996;334(11):693-700.
16. Ishiguro S, Inoue M, Tanaka Y, Mizokami M, Iwasaki M, Tsugane S, et al; JPHC Study Group. Serum aminotransferase level and the risk of hepato- cellular carcinoma: a population-based cohort study in Japan. Eur J Cancer Prev. 2009;18(1):26-32.
17. Suruki R, Hayashi K, Kusumoto K, Uto H, Ido A, Tsubouchi H, et al. Al- anine aminotransferase level as a predictor of hepatitis C virus-associated hepatocellular carcinoma incidence in a community-based population in Ja- pan. Int J Cancer 2006;119(1):192-195.
18. Wen C, Lin J, Yang Y, Tsai MK, Tsao CK, Etzel C, et al. Hepatocellular carcinoma risk prediction model for the general population: the predictive power of transaminases. J Natl Cancer Inst 2012;104(20):1599-1611.
19. Carr IB, Guerra V. A hepatocellular carcinoma aggressiveness index and its relationship to liver enzyme levels. Oncology 2016;90(4):215-220.
20. Tarao K, Takemiya S, Tamai S, Sugimasa Y, Ohkawa S, Akaike M, et al. Relationship between the recurrence of hepatocellular carcinoma (HCC) and serum alanine aminotransferase levels in hepatectomized patients with hepatitis C virus-associated cirrhosis and HCC. Cancer 1997;79(4):688- 694.
21. Hong Y, Chen Z, Wei L, Ma XK, Li X, Wen JY, et al. Identification of the prognostic value of lymphocyte-to-monocyte ratio in patients with HBV-as- sociated advanced hepatocellular carcinoma. Oncol Lett 2017;14(2):2089- 2096.
22. Zhao L, Yang D, Ma X, Liu MM, Wu DH, Zhang XP, et al. The Prognostic Value of aspartate aminotransferase to lymphocyte ratio and systemic im- mune-inflammation index for Overall Survival of Hepatocellular Carcino- ma Patients Treated with palliative Treatments. J Cancer 2019;10(10):2299- 2311.
23. Hung H, Lee J, Cheng C, Wu TH, Wang YC, Lee CF, et al. Impact of neutrophil to lymphocyte ratio on survival for hepatocellular carcinoma after curative resection. J Hepatobiliary Pancreat Sci 2017;24(10):559- 569.
24. Wang Y, Attar B, Fuentes H, Jaiswal P, Tafur AJ. Evaluation of the prog- nostic value of platelet to lymphocyte ratio in patients with hepatocellular carcinoma. J Gastrointest Oncol 2017;8(6):1065-1071.

APA	Aslanov S, ÜNAL N, Şenkaya A, ÇELİK F, buyruk A, Uysal A, AKYILDIZ M, TURAN I, gunsar f, Ersoz G, karasu z, Ozutemiz A, Akarca U (2022). Baseline characteristics associated with survival in patients with hepatocellular carcinoma. , 3 - 10. 10.14744/hf.2021.2021.0031
Chicago	Aslanov Seymur,ÜNAL NALAN GÜLSEN,Şenkaya Ali,ÇELİK Ferit,buyruk Abdullah murat,Uysal Alper,AKYILDIZ MURAT,TURAN ILKER,gunsar fulya,Ersoz Galip,karasu zeki,Ozutemiz Ahmet Omer,Akarca Ulus Salih Baseline characteristics associated with survival in patients with hepatocellular carcinoma. (2022): 3 - 10. 10.14744/hf.2021.2021.0031
MLA	Aslanov Seymur,ÜNAL NALAN GÜLSEN,Şenkaya Ali,ÇELİK Ferit,buyruk Abdullah murat,Uysal Alper,AKYILDIZ MURAT,TURAN ILKER,gunsar fulya,Ersoz Galip,karasu zeki,Ozutemiz Ahmet Omer,Akarca Ulus Salih Baseline characteristics associated with survival in patients with hepatocellular carcinoma. , 2022, ss.3 - 10. 10.14744/hf.2021.2021.0031
AMA	Aslanov S,ÜNAL N,Şenkaya A,ÇELİK F,buyruk A,Uysal A,AKYILDIZ M,TURAN I,gunsar f,Ersoz G,karasu z,Ozutemiz A,Akarca U Baseline characteristics associated with survival in patients with hepatocellular carcinoma. . 2022; 3 - 10. 10.14744/hf.2021.2021.0031
Vancouver	Aslanov S,ÜNAL N,Şenkaya A,ÇELİK F,buyruk A,Uysal A,AKYILDIZ M,TURAN I,gunsar f,Ersoz G,karasu z,Ozutemiz A,Akarca U Baseline characteristics associated with survival in patients with hepatocellular carcinoma. . 2022; 3 - 10. 10.14744/hf.2021.2021.0031
IEEE	Aslanov S,ÜNAL N,Şenkaya A,ÇELİK F,buyruk A,Uysal A,AKYILDIZ M,TURAN I,gunsar f,Ersoz G,karasu z,Ozutemiz A,Akarca U "Baseline characteristics associated with survival in patients with hepatocellular carcinoma." , ss.3 - 10, 2022. 10.14744/hf.2021.2021.0031
ISNAD	Aslanov, Seymur vd. "Baseline characteristics associated with survival in patients with hepatocellular carcinoma". (2022), 3-10. https://doi.org/10.14744/hf.2021.2021.0031

APA	Aslanov S, ÜNAL N, Şenkaya A, ÇELİK F, buyruk A, Uysal A, AKYILDIZ M, TURAN I, gunsar f, Ersoz G, karasu z, Ozutemiz A, Akarca U (2022). Baseline characteristics associated with survival in patients with hepatocellular carcinoma. Hepatology forum, 3(1), 3 - 10. 10.14744/hf.2021.2021.0031
Chicago	Aslanov Seymur,ÜNAL NALAN GÜLSEN,Şenkaya Ali,ÇELİK Ferit,buyruk Abdullah murat,Uysal Alper,AKYILDIZ MURAT,TURAN ILKER,gunsar fulya,Ersoz Galip,karasu zeki,Ozutemiz Ahmet Omer,Akarca Ulus Salih Baseline characteristics associated with survival in patients with hepatocellular carcinoma. Hepatology forum 3, no.1 (2022): 3 - 10. 10.14744/hf.2021.2021.0031
MLA	Aslanov Seymur,ÜNAL NALAN GÜLSEN,Şenkaya Ali,ÇELİK Ferit,buyruk Abdullah murat,Uysal Alper,AKYILDIZ MURAT,TURAN ILKER,gunsar fulya,Ersoz Galip,karasu zeki,Ozutemiz Ahmet Omer,Akarca Ulus Salih Baseline characteristics associated with survival in patients with hepatocellular carcinoma. Hepatology forum, vol.3, no.1, 2022, ss.3 - 10. 10.14744/hf.2021.2021.0031
AMA	Aslanov S,ÜNAL N,Şenkaya A,ÇELİK F,buyruk A,Uysal A,AKYILDIZ M,TURAN I,gunsar f,Ersoz G,karasu z,Ozutemiz A,Akarca U Baseline characteristics associated with survival in patients with hepatocellular carcinoma. Hepatology forum. 2022; 3(1): 3 - 10. 10.14744/hf.2021.2021.0031
Vancouver	Aslanov S,ÜNAL N,Şenkaya A,ÇELİK F,buyruk A,Uysal A,AKYILDIZ M,TURAN I,gunsar f,Ersoz G,karasu z,Ozutemiz A,Akarca U Baseline characteristics associated with survival in patients with hepatocellular carcinoma. Hepatology forum. 2022; 3(1): 3 - 10. 10.14744/hf.2021.2021.0031
IEEE	Aslanov S,ÜNAL N,Şenkaya A,ÇELİK F,buyruk A,Uysal A,AKYILDIZ M,TURAN I,gunsar f,Ersoz G,karasu z,Ozutemiz A,Akarca U "Baseline characteristics associated with survival in patients with hepatocellular carcinoma." Hepatology forum, 3, ss.3 - 10, 2022. 10.14744/hf.2021.2021.0031
ISNAD	Aslanov, Seymur vd. "Baseline characteristics associated with survival in patients with hepatocellular carcinoma". Hepatology forum 3/1 (2022), 3-10. https://doi.org/10.14744/hf.2021.2021.0031